Section Arrow
Quote
UTHR.NASDAQ
- United Therapeutics Corp
Quotes are at least 15-min delayed:2024/10/31 18:32 EDT
Last
 373.94
+12.54 (+3.47%)
Day High 
375.175 
Prev. Close
361.4 
1-M High
377.03 
Volume 
585.36K 
Bid
282.46
Ask
590.82
Day Low
359.705 
Open
362.54 
1-M Low
342.02 
Market Cap 
16.08B 
Currency USD 
P/E 16.61 
%Yield -- 
10-SMA 359.74 
20-SMA 358.25 
50-SMA 354.1 
52-W High 377.03 
52-W Low 208.6249 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
21.76/27.07
Enterprise Value
16.38B
Balance Sheet
Book Value Per Share
128.05
Cash Flow
Cash Flow Yield
0.06
Income Statement
Total Revenue
2.33B
Operating Revenue Per Share
33.85
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ELABElevai Labs0.059-0.0339-36.49%-- 
AVTEAerovate Therapeutics2.46+0.27+12.33%-- 
ENSCEnsysce Biosciences0.5754-0.0629-9.85%-- 
TNXPTonix Pharmaceuticals Holding Corp.0.1445-0.0099-6.41%-- 
GLYCGlycoMimetics0.4069-0.0496-10.87%-- 
Quotes are at least 15-min delayed：2024/10/31 18:32 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus onthe prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.